| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EPHA4 |
| Uniprot No | P54764 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 570-986aa |
| 氨基酸序列 | SRRRSKYSKAKQEADEEKHLNQGVRTYVDPFTYEDPNQAVREFAKEIDAS CIKIEKVIGVGEFGEVCSGRLKVPGKREICVAIKTLKAGYTDKQRRDFLS EASIMGQFDHPNIIHLEGVVTKCKPVMIITEYMENGSLDAFLRKNDGRFT VIQLVGMLRGIGSGMKYLSDMSYVHRDLAARNILVNSNLVCKVSDFGMSR VLEDDPEAAYTTRGGKIPIRWTAPEAIAYRKFTSASDVWSYGIVMWEVMS YGERPYWDMSNQDVIKAIEEGYRLPPPMDCPIALHQLMLDCWQKERSDRP KFGQIVNMLDKLIRNPNSLKRTGTESSRPNTALLDPSSPEFSAVVSVGDW LQAIKMDRYKDNFTAAGYTTLEAVVHVNQEDLARIGITAITHQNKILSSV QAMRTQMQQMHGRMVPV |
| 预测分子量 | 73 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EPHA4重组蛋白的3篇参考文献示例(注：文献为模拟构造，仅供参考)：
---
1. **文献名称**: *"Expression and Functional Characterization of Recombinant EPHA4 Tyrosine Kinase in Mammalian Cells"*
**作者**: Smith, J. et al.
**摘要**: 研究报道了在HEK293细胞中高效表达重组人源EPHA4酪氨酸激酶结构域，并通过体外激酶实验验证其活性，为靶向药物筛选提供工具。
2. **文献名称**: *"Structural Insights into EPHA4 Receptor-Ligand Interactions via Crystallography of Recombinant Ectodomain Complexes"*
**作者**: Tanaka, K. et al.
**摘要**: 利用重组EPHA4胞外段蛋白与配体ephrin-A5共结晶，解析了复合物三维结构，揭示了结合界面的关键氨基酸残基及信号传导机制。
3. **文献名称**: *"Recombinant EPHA4-Fc Fusion Protein Attenuates Spinal Cord Injury in a Rodent Model"*
**作者**: Lee, H. et al.
**摘要**: 开发了EPHA4-Fc重组融合蛋白，证明其通过竞争性抑制内源性Ephrin信号，促进脊髓损伤后神经轴突再生和功能恢复。
---
**备注**：以上文献为模拟示例，实际引用需查询PubMed、Web of Science等数据库获取真实研究。建议使用关键词“EPHA4 recombinant protein expression”、“EPHA4 structural analysis”或“EPHA4 therapeutic application”进一步检索。
**Background of EPHA4 Recombinant Protein**
Ephrin receptor A4 (EPHA4) belongs to the Eph receptor tyrosine kinase family, which plays pivotal roles in cell-cell communication, tissue patterning, and developmental processes. These receptors interact with membrane-bound ephrin ligands to mediate bidirectional signaling, influencing cell adhesion, migration, and axon guidance. EPHA4 is particularly notable for its involvement in nervous system development, including neural crest cell migration, spinal cord circuitry formation, and synaptic plasticity. Dysregulation of EPHA4 signaling has been implicated in pathologies such as amyotrophic lateral sclerosis (ALS), cancer metastasis, and spinal cord injury, making it a therapeutic target of interest.
Recombinant EPHA4 protein is engineered through molecular cloning and expression systems (e.g., mammalian cells, *E. coli*) to produce purified, functional forms of the receptor. This typically includes the extracellular domain, which mediates ligand binding, or full-length variants for structural and functional studies. The recombinant protein retains critical post-translational modifications (e.g., glycosylation) when produced in mammalian systems, ensuring biological relevance.
Researchers utilize EPHA4 recombinant protein to study receptor-ligand interactions, screen for inhibitors or activators, and elucidate signaling mechanisms. Its applications extend to *in vitro* assays (e.g., binding kinetics, phosphorylation studies) and *in vivo* models to explore therapeutic interventions. Quality control via techniques like SDS-PAGE, Western blotting, and activity assays ensures batch consistency. By providing a standardized tool, EPHA4 recombinant protein accelerates both basic research and drug development aimed at modulating this pathway in disease contexts.
×
